Skip to main content
Clinical Trials/NL-OMON40004
NL-OMON40004
Completed
Not Applicable

The role of β-adrenergic stress hormones in Eye Movement Desensitization and Reprocessing (EMDR). Part I: the effects of β-adrenergic receptor antagonist propranolol on the plasticity of emotionally arousing episodic memories. - The role of β-adrenergic stress hormones in EMDR: a propranolol study

niversiteit Utrecht0 sites60 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Geen aandoening: geneesmiddel wordt gebruikt om de onderliggende neurobiologische processen te onderzoeken van een therapie voor PTSD, namelijk EMDR
Sponsor
niversiteit Utrecht
Enrollment
60
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
August 5, 2014
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Passing the medical screening (ECG, blood pressure and heart rate examination, two\-step test and interview)
  • \- Age 18\-35
  • \- BMI 17\.5\-26
  • \- Normal (or corrected to normal) vision
  • \- In females: the use of reliable contraceptives (birth control pills or a hormonal intrauterine device)

Exclusion Criteria

  • Assessed with physical exam:
  • \- Abnormal ECG
  • \- Systolic blood pressure \< 60mmHg; Diastolic blood pressure \< 90 mmHg
  • \- Heart rate \< 60 bpm or \> 100 bpm
  • \- No \<10% increase in heart rate after 1 minute of stepping up and down a stepladder.;Assesed with interview:
  • \- Familiarity with EMDR and/or prior participation in EMDR research
  • \- Lifetime history of psychiatric disorder (depression, mania, psychosis, anxiety)
  • \- Lifetime history of neurological disease (attention/memory problems and disorders, epilepsy, convulsions)
  • \- Lifetime history of any cardiovascular problem, coronary insufficiency, congestive heart failure, heart block, bradycardia, myocardial infarction, hypotension, chronic obstructive pulmonary disease, bronchial asthma, renal disorders, liver disorders, uraemia, hyperthyroidism, acidosis.
  • \- Early age cardiovascular problems in first degree family members

Outcomes

Primary Outcomes

Not specified

Similar Trials